Please assess the completion status of the following clinical trial:

Trial Title: Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Provide signed and dated informed consent form~* Willing to comply with all study procedures and be available for the duration of the study~* Male or female, aged 50-80~* In sufficiently good general health to be able to have a FFA~* CNV diagnosed by OCT~* Vision equal or better than 6/60 in the study eye~* No prior treatment in the study eye with anti-VEGF medication~Exclusion Criteria~* Significant media opacity.~* Known allergic reactions to components of the study product(s).~* Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Naive wet age-related macular degeneration (Type: None): Patients recruited to the study will be patients who meet the Australian MBS criteria for treatment of exudative CNV with Lucentis. For the duration of the study, the patients will have standard induction and monthly dosing of Lucentis (Ranibizumab; intravitreal; 0.5 mg) to allow comparison with published studies. The only extra intervention for the study is the acquisition of hyperspectral mages with the hyperspectral camera and the acquisition of additional fundus autofluorescence images to the clinical norm.

Based on this trial design, predict the completion outcome and termination type (if applicable).